The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer

Abstract

Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.

Keywords

• atx
• chemoprevention
• cirrhosis
• fibrosis
• hcc
• hepatocellular carcinoma
• lpa
• lpar1
• nash
• non-alcoholic steatohepatitis